Medicare to cover obesity drugs, but not for weight loss

Source

Medicare to cover obesity drugs, but not for weight loss

“CMS has issued guidance to Medicare Part D plans stating that anti-obesity medications (AOMs) that receive FDA approval for an additional medically accepted indication can be considered a Part D drug for that specific use,” the spokesperson added, specifying that drugs that are FDA-approved for only weight loss do not fall under this consideration.

Wegovy, Rybelsus, and Ozempic, are the different brand names for Semaglutide. They have a black box warning for Medullary thyroid cancer.* 🤦🏼‍♀️

Related:

Wegovy side effects: What you should know

*Obesity and Cancer

[2022] The Dark History of Medicare Privatization

Medicare Advantage was supposed to be a money-saver. It’s now become a costly, unaccountable cash cow for private insurance companies that is swallowing traditional Medicare.

The Dark History of Medicare Privatization

Related:

Medicare goes “woke”?! 😉

CMS Unveils ACO REACH: What you Need to Know

The Geo Direct Contracting model is scrapped, and ACO REACH is replacing GPDC…

A new incentive will help to address health equity.

Blue Cross Blue Shield Association

Blue Cross and Blue Shield insurance companies are licensees, independent of the association and traditionally of each other, offering insurance plans within defined regions under one or both of the association’s brands. Blue Cross Blue Shield insurers offer some form of health insurance coverage in every U.S. state. They also act as administrators of Medicare in many states or regions of the U.S.